Semaglutide
Refilling Soon
This peptide is currently out of stock. Get notified the moment it's available.
About Semaglutide
Semaglutide is a long-acting GLP-1 (Glucagon-Like Peptide-1) receptor agonist that has become one of the most clinically validated metabolic compounds in modern medicine. Approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), semaglutide's research applications extend well beyond glycaemic control. It stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite through central hypothalamic pathways — a multi-organ metabolic profile that makes it one of the most mechanistically rich GLP-1 agonists available for research. Cardiovascular outcomes research (SUSTAIN-6, SELECT trials) has demonstrated significant reductions in major adverse cardiovascular events — a pleiotropic benefit that has driven substantial mechanistic research interest. Emerging research areas include GLP-1 receptor signalling in neurodegeneration (Parkinson's and Alzheimer's models), hepatic steatosis reversal, addiction and reward pathway modulation, and polycystic ovary syndrome. Semaglutide's 168-hour half-life — achieved through C18 fatty diacid albumin binding — makes it ideal for sustained GLP-1 receptor engagement studies. Supplied at ≥99% HPLC purity.
Usage Guidelines
✓ Suitable For
- Premier GLP-1 agonist research compound with extensive clinical validation and published data
- Ideal for metabolic syndrome obesity and cardiovascular risk mechanism research
- Valuable for neurodegeneration NAFLD and addiction pathway research given broad receptor distribution
- Long half-life suits weekly dosing research designs requiring sustained GLP-1 engagement
✗ Not Recommended For
- Not for use without medical supervision — GLP-1 agonists require careful dose titration
- Not suitable for individuals with personal or family history of medullary thyroid carcinoma
- Gastrointestinal side effects are common during initiation — monitor research subjects
- Consult an endocrinologist or metabolic specialist before beginning any semaglutide protocol